CEOs Worldwide Show Rising Confidence and Unprecedented Adaptability Amid Unrelenting Uncertainty
23.10.2025 14:00:00 CEST | Business Wire | Press Release
Global CEOs are meeting ongoing volatility with renewed confidence and agility, according to The CEO Response, Egon Zehnder’s latest study of 1,235 chief executives.
The research reveals that 92% of CEOs believe they must cultivate unprecedented levels of adaptability to lead effectively through current geopolitical and economic disruption. Yet most feel more capable and confident than a year ago, having turned recent crises into lasting lessons in resilience.
“CEOs are increasingly adjusting to the rapidly changing world order, characterized by fragmented alliances, strategic resource shortages, new technologies, and the power of individual actors,” said Lars-Hendrik Röller, Founder and Chair of the Berlin Global Dialogue. “They are guided by a key insight: Either they help shape the rules of the new order—or they are completely exposed to its complex developments.”
Nearly six in ten CEOs (59%) view agility and adaptability as the most critical factor for business success today, while 87% cite geopolitical instability as their greatest challenge. To stay ahead, CEOs are focusing investments on innovation (53%), artificial intelligence (44%), and employee development (42%).
The report also finds that 97% of CEOs see opportunities to contribute to global prosperity, signaling a broader sense of purpose in leadership. Nearly all (99%) emphasize cultivating organizational cultures of curiosity and open-mindedness as essential for navigating complexity.
Launched during this year’s Berlin Global Dialogue (BGD), the study underscores a shift in leadership. Under the theme, “Shifting Power, Shaping Prosperity,” BGD convenes high-ranking international government representatives and business leaders to forge new partnerships and make strategic decisions in a multipolar world.
“CEOs have shown an extraordinary ability to learn from and adapt amid uncertainty and global instability. Beyond managing crises and business upheavals, they are actively defining how to contribute to global prosperity, whether through their business practices or by engaging beyond the boundaries of their organizations,” comments Michael Ensser, Global Chair of Egon Zehnder, on the study’s findings. “Leadership today means forging new paths with strategic foresight, pragmatism, and collective intelligence. Many leaders have recently invested specifically in honing these skills. That investment is now paying off.”
As global dynamics continue to shift, The CEO Response underscores a pivotal moment in leadership evolution. CEOs are no longer reacting to uncertainty – they are using it as a catalyst for growth, innovation, and progress. Egon Zehnder’s findings reveal a generation of leaders that are redefining success through adaptability and purpose, setting a new standard for how organizations can thrive in an unpredictable world.
For more information and to access the full report, please visit: https://www.egonzehnder.com/the-ceo-response
About Egon Zehnder
Egon Zehnder is the world’s preeminent leadership advisory and executive search firm, inspiring leaders to navigate complex questions with human answers. We help organizations get to the heart of their leadership challenges and offer honest feedback and insights to help leaders realize their true being and purpose.
We are built on a foundation that supports partnership in the truest sense of the word and aligns our interests with the interests of our clients. Our 600 consultants across 68 offices and 36 countries are former industry and functional leaders who collaborate seamlessly to deliver the full power of the Firm to every client, every time. We believe that together we can transform people, organizations and the world through leadership.
About Berlin Global Dialogue
Berlin Global Dialogue (BGD) unites leaders from business, policy, and academia to develop joint solutions for the most pressing challenges impacting the global economy. Established in 2022, Berlin Global Dialogue emerged from the economic, political, and social realities of the twenty-first century as a new platform for a new era. Founded with the mission to strengthen the dialogue between different stakeholders, the annual summit convenes select high-level participants for candid exchanges in interactive formats that highlight diverse perspectives and facilitate cross-disciplinary collaboration.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251023652739/en/
Contacts
Media Contacts
Klara Schroeder, Berlin Global Dialogue
klara.schroeder@esmt.org
Cheryl Soltis Martel, Egon Zehnder
cheryl.martel@egonzehnder.com
Martin Klusmann, Egon Zehnder
Martin.klusmann@egonzehnder.com
Luisa Bond, Egon Zehnder
luisa.bond@egonzehnder.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom